Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases

Annals of the American Thoracic Society

Volumn 16, Issue 5, 2019, Pages 580-588

  Adegunsoye, Ayodeji ^a   Oldham, Justin M ^b   Bellam, Shashi K ^c   Montner, Steven ^a   Churpek, Matthew M ^a   Noth, Imre ^d   Vij, Rekha ^a   Strek, Mary E ^a   Chung, Jonathan H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

CT; Honeycombing; Interstitial lung disease; Mortality; Pulmonary fibrosis

Indexed keywords

ADULT; AGED; ALLERGIC PNEUMONITIS; ARTICLE; ASSOCIATION; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY RATE; OBSERVATIONAL STUDY; PHENOTYPE; PREVALENCE; PROPORTIONAL HAZARDS MODEL; SOCIAL SECURITY; SURVIVAL TIME; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; LUNG; LUNG FIBROSIS; MULTICENTER STUDY; PROCEDURES; PROGNOSIS; SURVIVAL RATE; UNITED STATES; X-RAY COMPUTED TOMOGRAPHY;

AGED; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; PHENOTYPE; PREVALENCE; PROGNOSIS; PULMONARY FIBROSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 85065030001     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201807-443OC     Document Type: Article

References (39)

1. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med 2018;378:1811–1823.
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788–824.
3. Salisbury ML, Tolle LB, Xia M, Murray S, Tayob N, Nambiar AM, et al. Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients. Respir Med 2017;131:229–235.
4. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183: 431–440.
5. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al.; American Thoracic Society; European Respiratory Society; Japanese Respiratory Society; Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ ALAT clinical practice guideline. Am J Respir Crit Care Med 2018;198: e44–e68.
6. Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, et al.; Idiopathic Pulmonary Fibrosis Study Group. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005;172:488–493.
7. Sumikawa H, Johkoh T, Colby TV, Ichikado K, Suga M, Taniguchi H, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008; 177:433–439.
8. Watadani T, Sakai F, Johkoh T, Noma S, Akira M, Fujimoto K, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 2013;266:936–944.
9. Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch Pathol Lab Med 2012;136:591–600.
10. Raghu G, Lynch D, Godwin JD, Webb R, Colby TV, Leslie KO, et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med 2014;2:277–284.
11. Morell F, Villar A, Montero MA, Muñoz X, Colby TV, Pipvath S, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013;1:685–694.
12. Johkoh T, Sakai F, Noma S, Akira M, Fujimoto K, Watadani T, et al. Honeycombing on CT; its definition, pathologic correlation, and future direction of its diagnosis. Eur J Radiol 2014;83:27–31.
13. Jacob J, Song JW, Yoon HY, Cross G, Barnett J, Woo WL, et al. Prevalence and effects of emphysema in never-smokers with rheumatoid arthritis interstitial lung disease. EBioMedicine 2018;28: 303–310.
14. Adegunsoye A, Oldham JM, Chung JH, Montner SM, Lee C, Witt LJ, et al. Phenotypic clusters predict outcomes in a longitudinal interstitial lung disease cohort. Chest 2018;153:349–360.
15. Tateishi T, Ohtani Y, Takemura T, Akashi T, Miyazaki Y, Inase N, et al. Serial high-resolution computed tomography findings of acute and chronic hypersensitivity pneumonitis induced by avian antigen. J Comput Assist Tomogr 2011;35:272–279.
16. Yunt ZX, Chung JH, Hobbs S, Fernandez-Perez ER, Olson AL, Huie TJ, et al. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: relationship to survival. Respir Med 2017;126:100–104.
17. Chung JH, Zhan X, Cao M, Koelsch TL, Manjarres DCG, Brown KK, et al. Presence of air trapping and mosaic attenuation on chest computed tomography predicts survival in chronic hypersensitivity pneumonitis. Ann Am Thorac Soc 2017;14:1533–1538.
18. Nurmi HM, Kettunen HP, Suoranta SK, Purokivi MK, Karkkainen MS, Selander TA, et al. Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease. Respir Med 2018;134: 24–30.
19. Oldham JM, Adegunsoye A, Valenzi E, Lee C, Witt L, Chen L, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 2016;47:1767–1775.
20. Adegunsoye AO, Chung JH, Bellam SK, Oldham J, Montner S, Churpek MM, et al. CT honeycombing fibrosis is prevalent and associated with mortality across diverse interstitial lung diseases [abstract]. Am J Respir Crit Care Med 2018;197:A2536.
21. Adegunsoye A, Oldham JM, Bellam SK, Chung JH, Chung PA, Biblowitz KM, et al. African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. Eur Respir J 2018;51:1800255.
22. Adegunsoye A, Oldham JM, Bonham C, Hrusch C, Nolan P, Klejch W, et al. Prognosticating outcomes in interstitial lung disease by mediastinal lymph node assessment: an observational cohort study with independent validation. Am J Respir Crit Care Med [online ahead of print] 14 Sep 2018; DOI: 10.1164/rccm.201804-0761OC.
23. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al.; ATS/ERS Committee on Idiopathic Pulmonary Fibrosis. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733–748.
24. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277–304. [Published erratum appears in Am J Respir Crit Care Med 166:426.]
25. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al.; ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015;46:976–987.
26. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al.; American Thoracic Society; European Respiratory Society; Japanese Respiratory Society; Latin American Thoracic Association. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192:e3–e19.
27. Mai C, Verleden SE, McDonough JE, Willems S, De Wever W, Coolen J, et al. Thin-section CT features of idiopathic pulmonary fibrosis correlated with micro-CT and histologic analysis. Radiology 2017; 283:252–263.
28. Guler SA, Ellison K, Algamdi M, Collard HR, Ryerson CJ. Heterogeneity in unclassifiable interstitial lung disease: a systematic review and meta-analysis. Ann Am Thorac Soc 2018;15:854–863.
29. Salisbury ML, Gu T, Murray S, Gross BH, Chughtai A, Sayyouh M, et al. Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest [online ahead of print] 19 Sep 2018; DOI: 10.1016/j.chest.2018.08.1076.
30. Podolanczuk AJ, Oelsner EC, Barr RG, Bernstein EJ, Hoffman EA, Easthausen IJ, et al. High-attenuation areas on chest computed tomography and clinical respiratory outcomes in community-dwelling adults. Am J Respir Crit Care Med 2017;196:1434–1442.
31. Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011;184:842–847.
32. Adegunsoye A, Strek ME, Garrity E, Guzy R, Bag R. Comprehensive care of the lung transplant patient. Chest 2017;152:150–164.
33. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, IPF Consensus Working Group. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018;51:1800692.
34. Ryerson CJ. Lumpers versus splitters: what to do with suspected idiopathic pulmonary fibrosis? Respirology [online ahead of print] 15 Nov 2018; DOI: 10.1111/resp.13442.
35. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respir Res 2018;5: e000289.
36. Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res 2017;4:e000212.
37. Chung JH, Chawla A, Peljto AL, Cool CD, Groshong SD, Talbert JL, et al. CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. Chest 2015;147:450–459.
38. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 2018;6: 138–153.
39. Chung JH, Oldham JM, Montner SM, Vij R, Adegunsoye A, Husain AN, et al. CT-pathologic correlation of major types of pulmonary fibrosis: insights for revisions to current guidelines. AJR Am J Roentgenol 2018;210:1034–1041.